cultivate(MD)
VC Fund
Holland, United States
cultivate(MD) is a unique, medical venture capital fund.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
- Fund size:
- $6.1M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries cultivate(MD) invests in
Medical DeviceHealth CareBiotechnologyMedicalSoftware
Stages cultivate(MD) invests in
Series ASeedFunding RoundSeries BSeries C
Countries cultivate(MD) invests in
United StatesEl Salvador
Round sizes
Seed $678k–$4.5MSeries A $1.6M–$9.3M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $678k–$4.5M
- Series A
- $1.6M–$9.3M
Investment Focus
Industry
- Medical Device 9 (53%)
- Health Care 7 (41%)
- Biotechnology 5 (29%)
- Medical 4 (24%)
- Software 3 (18%)
Stage
- Series A 5 (29%)
- Seed 4 (24%)
- Funding Round 2 (12%)
- Series B 1 (6%)
- Series C 1 (6%)
Country
- United States 11 (65%)
- El Salvador 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Don Running
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Rob Ball
Managing Director
|
Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NANOCHON
|
Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $4.1M / Seed / Jan 12, 2026 | |
Prana Thoracic
|
Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US.The paradigm of screening, detection, and early intervention that has beendeployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer.Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early. | $3M / Series A / Jun 18, 2024 | |
|
NANOCHON
|
Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $4M / Seed / May 06, 2024 | |
|
NANOCHON
|
Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | Seed / Nov 27, 2023 | |
Virtual Incision
|
Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $30M / Series C / Sep 19, 2023 | |
SentiAR
|
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $8.5M / Series B / Apr 11, 2023 | |
Shoulder Innovations
|
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $42M / Series D / Mar 06, 2023 | |
SpinTech MRI
|
SpinTech is developed a MRI imaging software platform that drastically reduces the time required for brain imaging while enhancing visualization, quantification, and automatic detection of biomarkers critical to proper diagnosis of neurological conditions such as traumatic brain injury, dementia, Parkinson's, Multiple Sclerosis, and stroke,but that are unseen with current techniques. they are physicists, engineers, and entrepreneurs committed to bringing the future of imaging technology to every patient suffering from neurological disease, offering quantitative image processing previously reserved for only a handful of research institutions, in a cost effective, workflow-efficient software platform that improves patient outcomes and maximizes the return on investment for costly imaging equipment. | $6.5M / Series A / Jul 18, 2022 | |
Strados Labs
|
Strados Labs is a medical technology company that innovates respiratory monitoring using smart biosensors and artificial intelligence. The company specializes in advancing respiratory health management using clinical-grade biosensors and intelligent software. It connects people with real-time respiratory monitoring using a wearable device andconnected mobile platform so they can quantify their health and make more informed decisions.The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania. | $4.5M / Seed / Jul 29, 2021 | |
Deepstash
|
Our core belief: ideas are fundamental.If we evolve our biology through genes, it's what we hold in our brains that help shape our lives and improve the world around us. Ideas represent the building blocks of the modern world, informing our thinking and behavior every day. New ideas breathe fresh life into how we view the world & wedepend on new ideas to improve our health, productivity or our relationships.Ideas used to be reserved for the rich and powerful who had access to knowledge. Whether the king or the priest, it was those at the top that control information. With the advent of the Internet, the pendulum has swing the other side. We have so much access to information that it becomes overwhelming. There is too much to absorb and not enough time. Not to mention the socially enabled magical devices we carry in our pockets can keep our minds constantly distracted with divisive news & silly entertainment.Deepstash is platform for finding and organizing the ideas that matter to you. We are a passionate community obsessed with finding the Aha moments in all the content we are consuming. We are condensing all our insights into ideas that we share with all the other stashes who are sharing our passion. It's what we call stashing!The Deepstash app is available on the Apple App Store, Google Play as well as on the Web. | $3.6M / Seed / Dec 04, 2020 | |
| See all 17 investments → | |||
Co-Investors
Genesis Innovation Group
2 deals together
Michigan Angel Fund
2 deals together
Wakestream Ventures
2 deals together
757 Angels powered by VentureSouth
1 deal together
Alumni Ventures
1 deal together
Aperture Venture Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does cultivate(MD) invest in?
cultivate(MD) invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is cultivate(MD)'s check size?
cultivate(MD) typically joins rounds of $678k–$4.5M at Seed and $1.6M–$9.3M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds cultivate(MD) participates in.
How do I contact cultivate(MD)?
Public channels for cultivate(MD) include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at cultivate(MD)?
The team at cultivate(MD) includes Don Running (Managing Director) and Rob Ball (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
